Colruyt Group’s Impressive Financial Performance in 2022-2023: A Closer Look at NewPharma and Expansion Strategies

2023-06-14 16:32:57

Colruyt Group presented on June 13 its figures for the 2022-2023 financial year, up 7.7% to reach 10.8 billion euros. In contrast, profit for the year fell 30.4% to 201 million euros. According to the company, the turnover was positively influenced by the increase in turnover of the fuel-related activities of DATS 24, the full consolidation of Roelandt Group and NewPharma and the increase in food inflation.

When you are profitable, you have money or you are perhaps a leader in a small market, what else can you do but grow? Either by going to other areas of commerce, which they did: Dreambaby without much success. But there are other cases where they invest in NewPharma, the online pharmacy. They created Bike Republic on bike mobility, and that sort of thing. So will it all work like Colruyt? Maybe not, but at some point you can’t go faster than the machine“, comments the editor-in-chief of Gondola Magazine Christophe Sancy, interviewed regarding La Première.

1686767119
#Colruyt #closeup #Belgian #family #business #employs #people

Leave a Replay